Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease

Arthritis and Rheumatism

Volumn 63, Issue 8, 2011, Pages 2484-2494

  Gan, Ye ^a   Reilkoff, Ronald ^b   Peng, Xueyan ^b   Russell, Thomas ^b   Chen, Qingsheng ^b   Mathai, Susan K ^b   Homer, Robert ^c   Gulati, Mridu ^b   Siner, Jonathan ^b   Elias, Jack ^b   Bucala, Richard ^b   Herzog, Erica ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD19 ANTIGEN; CD45 ANTIGEN; MESSENGER RNA; NEUTRALIZING ANTIBODY; SEMAPHORIN; SEMAPHORIN 7A; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL GROWTH; CELL STIMULATION; CONTROLLED STUDY; GENE; GENE DELETION; GENE DISRUPTION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCLERODERMA;

ADULT; ANIMALS; ANTIGENS, CD29; DISEASE MODELS, ANIMAL; FIBROBLASTS; HUMANS; LUNG DISEASES, INTERSTITIAL; MICE; MICE, KNOCKOUT; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SEMAPHORINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79961100313     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30386     Document Type: Article

References (42)

1. Eickholt BJ,. Functional diversity and mechanisms of action of the semaphorins. Development 2008; 135: 2689-94.
2. Kumanogoh A, Kikutani H,. Immune semaphorins: a new area of semaphorin research. J Cell Sci 2003; 116: 3463-70. (Pubitemid 37063390)
3. Lazova R, Gould Rothberg BE, Rimm D, Scott G,. The semaphorin 7A receptor Plexin C1 is lost during melanoma metastasis. Am J Dermatopathol 2009; 31: 177-81.
4. Maruyama T, Matsuura M, Suzuki K, Yamamoto N,. Cooperative activity of multiple upper layer proteins for thalamocortical axon growth. Dev Neurobiol 2008; 68: 317-31. (Pubitemid 351263622)
5. Pasterkamp RJ, Peschon JJ, Spriggs MK, Kolodkin AL,. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 2003; 424: 398-405. (Pubitemid 36917482)
6. Holmes S, Downs AM, Fosberry A, Hayes PD, Michalovich D, Murdoch P, et al. Sema7A is a potent monocyte stimulator. Scand J Immunol 2002; 56: 270-5. (Pubitemid 35002031)
7. Suzuki K, Okuno T, Yamamoto M, Pasterkamp RJ, Takegahara N, Takamatsu H, et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through α1β1 integrin. Nature 2007; 446: 680-4. (Pubitemid 46606878)
8. Scott GA, McClelland LA, Fricke AF,. Semaphorin 7a promotes spreading and dendricity in human melanocytes through β1-integrins. J Invest Dermatol 2008; 128: 151-61. (Pubitemid 350249386)
9. Kang HR, Lee CG, Homer RJ, Elias JA,. Semaphorin 7A plays a critical role in TGF-β1-induced pulmonary fibrosis. J Exp Med 2007; 204: 1083-93. (Pubitemid 46798152)
10. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A,. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1: 71-81.
11. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN,. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001; 166: 7556-62. (Pubitemid 32525636)
12. Mehrad B, Burdick MD, Strieter RM,. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009; 41: 1708-18.
13. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 438-46. (Pubitemid 39071616)
14. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB,. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006; 35: 175-81. (Pubitemid 44175316)
15. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM,. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007; 353: 104-8. (Pubitemid 44958347)
16. Wang CH, Huang CD, Lin HC, Lee KY, Lin SM, Liu CY, et al. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit Care Med 2008; 178: 583-91.
17. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010; 90: 812-23.
18. Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002; 99: 3908-13. (Pubitemid 34252204)
19. Varga J, Pasche B,. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-6.
20. Steen VD, Medsger TA,. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4. (Pubitemid 46999798)
21. Harrison NK, McAnulty RJ, Haslam PL, Black CM, Laurent GJ,. Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis. Thorax 1990; 45: 606-10. (Pubitemid 20270479)
22. Harrison NK, Myers AR, Corrin B, Soosay G, Dewar A, Black CM, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144: 706-13.
23. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
24. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102: 150-5. (Pubitemid 350151821)
25. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford); 49: 271-80.
26. D'Ovidio F, Singer LG, Hadjiliadis D, Pierre A, Waddell TK, de Perrot M, et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 2005; 80: 1254-60. (Pubitemid 41354098)
27. D'Ovidio F, Mura M, Tsang M, Waddell TK, Hutcheon MA, Singer LG, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005; 129: 1144-52. (Pubitemid 40631438)
28. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor β1-induced pulmonary fibrosis. J Exp Med 2004; 200: 377-89. (Pubitemid 39031256)
29. Herzog EL, Van Arnam J, Hu B, Krause DS,. Threshold of lung injury required for the appearance of marrow-derived lung epithelia. Stem Cells 2006; 24: 1986-92. (Pubitemid 44474175)
30. Bungartz G, Stiller S, Bauer M, Muller W, Schippers A, Wagner N, et al. Adult murine hematopoiesis can proceed without β1 and β7 integrins. Blood 2006; 108: 1857-64. (Pubitemid 44394994)
31. Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, et al. TGF-β driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol 2011; 43: 154-62.
32. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
33. Murray LA, Rosada R, Moreira AP, Joshi A, Kramer MS, Hesson DP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One; 5: e9683.
34. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, et al. A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol; 130: 694-705.
35. Pilling D, Fan T, Huang D, Kaul B, Gomer RH,. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 2009; 4: e7475.
36. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S,. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003; 171: 380-9. (Pubitemid 36745311)
37. Herzog EL, Bucala R,. Fibrocytes in health and disease. Exp Hematol 2010; 38: 548-56.
38. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588-94.
39. Broen J, Gourh P, Rueda B, Coenen M, Mayes M, Martin J, et al, for the European Consortium on Systemic Sclerosis Genetics. The FAS -670A>G polymorphism influences susceptibility to systemic sclerosis phenotypes. Arthritis Rheum 2009; 60: 3815-20.
40. Czopik AK, Bynoe MS, Palm N, Raine CS, Medzhitov R,. Semaphorin 7A is a negative regulator of T cell responses. Immunity 2006; 24: 591-600. (Pubitemid 43728148)
41. Luzina IG, Todd NW, Iacono AT, Atamas SP,. Roles of T lymphocytes in pulmonary fibrosis. J Leukoc Biol 2008; 83: 237-44. (Pubitemid 351225603)
42. + monocytes into fibrocytes. Proc Natl Acad Sci U S A 2009; 106: 17892-7.